(1 - 21 von 30
)
ARGEN-X (EBR:ARGX) argenx to present complete data from the Phase 2...
www.webdisclosure.com
... from current therapies for managing IgG levels, including plasmapheresis, where benefit reversed more rapidly," commented Nicolas Leupin, CMO of argenx.
ArgenX reports hints to efficacy of ARGX-113 in generalised...
european-biotechnology.com
... evaluating in our two ongoing Phase II studies in immune thrombocytopenia and pemphigus vulgaris," said ArgenX's CMO Nicolas Leupin.
arGEN X : argenx launches Phase II proof-of-concept clinical trial of...
www.marketscreener.com
Interim data expected in H September 26, Breda, the Netherlands / Ghent, Belgium - argenx , a clinical-stage biotechnology company developing a...
Initial Data on Candidate for Autoimmune Disease Reported - Lupus...
lupusnewstoday.com
Read more about argenx Reports Initial Data from Phase 1 Study of ARGX-113 in Healthy Volunteers
sortiert nach Relevanz / Datum